Patent · US Active

Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

US12285468B2 · kind B2 · utility

0Cited by

6References

16Claims

0Family size

Assignee

IPSEN BIOPHARM LIMITED · GB

Inventors

Anders JARSTAD · Uppsala, SE
Anna FRIIS · Uppsala, SE
Ulf Stahl · Bochum, DE
Ann GURELL · Stockholm, SE
Barbro AGREN · Mattmar, SE
Emilia EDSTROM · Uppsala, SE
Andrew PICKETT · Uppsala, SE

Key dates

Filing date	Sep 28, 2023
Grant date	Apr 29, 2025
Priority date	—
Expiry date	Sep 28, 2043

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.